The therapeutic applications of this medication are commonly used across two primary clinical domains, relating to its availability as a systemic injection and as a localized eye solution.

Acute Circulatory Support in Critical Settings

This preparation, when used as an injection, is commonly used for managing acute circulatory failure and severe hypotension in clinical settings that involve acute or unstable symptom patterns. It is applied when patients experience a clinically important drop in blood pressure, such as that caused by certain types of vasodilatory shock or by the effects of anesthesia. The therapeutic benefit supports the stabilization of systemic blood pressure, helping to maintain adequate blood flow (perfusion) to the body’s essential organs, which supports the patient during difficult episodes by easing systemic distress. Use of this medication is relevant in clinical contexts involving heightened systemic burden.

The main conditions addressed by the injection include acute hypotension occurring during anesthesia and vasodilatory shock, and it is applied in intensive care settings involving acute systemic needs.

Ocular Dilation for Examination and Therapy

As an ophthalmic solution, Мезатон is relevant for easing diagnostic obstruction in eye care. It helps achieve pupil dilation (mydriasis), which addresses the symptom of limited visual field relevant for a detailed assessment of the eye's internal structures. The drops also offer supportive relief in specific inflammatory eye conditions, such as anterior uveitis, where their use may assist with managing adhesions (synechiae) related to irritative states. This application is relevant when supportive symptom management is appropriate to support patients during episodes of discomfort.

---

Quick Fact: Relief for Severe Hypotension

---

Regulatory References

1. Phenylephrine Hydrochloride Injection FDA Label

Who can and cannot use Мезатон? (Phenylephrine)

This section defines population eligibility based strictly on government-approved labeling.

Eligibility scope	Status or Rule
Populations Contraindicated	Hypersensitivity to any component; Hypertension or Thyrotoxicosis (for 10% ophthalmic solution only) [Source 1.2, 1.5].
Age-Related Exclusion	Contraindicated in pediatric patients less than 1 year of age for the 10% ophthalmic solution [Source 1.2].
Age-Related Caution	Caution is advised for the 10% ophthalmic solution in children less than 5 years of age; Dose selection for geriatric patients requires caution due to potential decreased organ function [Source 1.1, 1.2].
Cardiovascular Restriction	Conditional use with caution is required for patients with severe arteriosclerosis, history of angina, or underlying heart failure, as use may exacerbate these conditions [Source 1.5].
Organ Function Restriction	Patients with End-Stage Renal Disease may have an increased response, while those with hepatic cirrhosis may require higher dosages [Source 1.1].
Pregnancy Eligibility	Systemic injection is designated Pregnancy Category C, meaning use is only permitted if the potential benefit justifies the potential risk to the fetus [Source 1.5].
Lactation Status	Caution should be exercised when administered to a nursing woman, as it is not known whether the drug is excreted in human breast milk [Source 1.2].

Official eligibility statements:

• The use of Phenylephrine is contraindicated in patients with a history of hypersensitivity to the drug [Source 1.5].
• Safety and effectiveness have not been established for the injectable solution in pediatric patients [Source 1.1].
• Restrictions are often dependent on the drug form/concentration (e.g., the 10% ophthalmic solution has explicit prohibitions) [Source 1.2].

Connection to the overall eligibility profile: Regulatory documents classify patients into groups that are allowed, contraindicated, or conditional based on underlying health and age. Due to its potent pressor effects, the drug carries explicit prohibitions for populations with certain cardiovascular conditions and age-based exclusions for specific high-concentration formulations. Conditional use requirements are detailed for patients with altered organ function (hepatic/renal) to manage potential augmented pressor response [Source 1.1, 1.2].

Interactions with other medicines and products

The interaction profile for Phenylephrine Hydrochloride is defined by its selective alpha-1 adrenergic activity, with documentation primarily focused on pharmacodynamic and metabolic interactions as classified by regulatory authorities.

Official Interaction Statements

Interaction Entity	Interaction Outcome and Restriction	Classification Type
Monoamine Oxidase Inhibitors (MAOIs)	Co-administration is formally contraindicated due to inhibition of Phenylephrine's metabolism, leading to increased exposure and risk of severe pressor crisis.	Contraindicated/Exposure-Modifying
Oxytocic Drugs, Tricyclic Antidepressants, Ergot Alkaloids	Documented to potentiate the vasopressor effect, increasing the risk of adverse cardiovascular outcomes, including severe hypertension.	Pharmacodynamic Potentiation
Inhalation Anesthetic Agents (e.g., Halothane)	May cause sensitization of the myocardium, increasing the risk of ventricular fibrillation or perioperative hypertensive crisis.	Pharmacodynamic

Procedural Constraints and Specific Cautions

A mandatory 14-day separation interval is required between the discontinuation of a Monoamine Oxidase Inhibitor and the administration of Phenylephrine. The official prescribing information also notes that the pressor response may be augmented in patients with certain conditions, such as Autonomic Dysfunction.

Selective Activation of Alpha-1 Adrenergic Receptors

Мезатон acts as a direct and highly selective agonist at the alpha1-adrenergic receptor (alpha1-AR), initiating a specific intracellular Gq protein cascade that culminates in the rapid release of stored calcium ions. This molecular mechanism results in the Ca^2+-mediated smooth muscle contraction across specific target tissues, which is the singular cellular action.

Modulation of Systemic Vascular Tone and Resistance

The smooth muscle contraction induced by alpha1-AR activation causes a generalized narrowing of the arteries and veins, a process known as vasoconstriction. This physiological change increases Systemic Vascular Resistance (SVR) and reduces venous capacitance, which increases venous return (preload), resulting in a rise in mean arterial pressure (MAP).

Local Ocular Muscle Contraction and Pupil Widening

The same calcium-dependent contractile mechanism acts on the eye, where alpha1-ARs are concentrated on the iris dilator muscle. Activation causes this muscle to contract and pull the iris radially outward, leading directly to the physiological effect of mydriasis, or pupil dilation.

Mechanistic Constraint via Baroreflex

A key constraint on the systemic mechanism is the body's baroreflex, a compensatory feedback loop triggered by the drug-induced pressure rise. This reflex acts to increase parasympathetic tone, resulting in the physiological consequence of reflex bradycardia (slowed heart rate) that modulates the heart rate and may constrain the resultant effect on cardiac output.

The use of Мезатон (phenylephrine hydrochloride) for acute blood pressure management is centered on its administration in a supervised clinical setting, such as during anesthesia or in the intensive care unit.

Administration Protocol

The medication is administered solely via the parenteral route (injection or infusion into a vein) by healthcare professionals. It is critical that volume depletion or acidosis be corrected before or during the use of the drug.

Administration Method	Recommended Adult Dosing	Frequency / Schedule
Intravenous (IV) Bolus	50 mcg to 250 mcg	May repeat boluses every 1–2 minutes as needed; do not exceed 200 mcg per single bolus.
Intravenous (IV) Infusion	0.5 mcg/kg/min to 6 mcg/kg/min	Administered as a continuous infusion, titrated to a defined blood pressure goal.

Preparation and Handling

The 10 mg/mL concentrate formulation must be diluted prior to intravenous administration. For bolus use, the concentrate is diluted to a final concentration of 100 mcg/mL, typically using 0.9% Sodium Chloride or 5% Dextrose Injection. For continuous infusion, the concentration is commonly prepared to 20 mcg/mL. The prepared solution must be visually inspected for particulate matter and discoloration before use.

Special Population Dosing

Treatment of older people should be carried out with care. Patients with renal impairment may require lower doses, while those with hepatic impairment (cirrhosis) may require higher doses. The safety and efficacy for use in the pediatric population are generally not established for this indication.

Research evidence / Overview of Studies for Мезатон (Phenylephrine)

Evidence for Use in Acute Circulatory Support (Injection)

Research into the systemic injectable form of Phenylephrine (Мезатон) has primarily focused on its use in managing outcomes related to systemic or functional imbalance, specifically acute low blood pressure (hypotension). Studies have been conducted during periods of increased symptom activity, such as during surgical procedures involving anesthesia or in intensive care settings with patients experiencing septic or vasodilatory shock. The available evidence includes randomized controlled trials (RCTs) and systematic reviews.

Research highlights measurements recorded during the study period, with studies reporting measurements of mean arterial pressure within the observed populations. Some trials described patterns observed in the studies related to changes in heart rate and cardiac output when comparing it with other medications used for the same purpose. However, comparative evidence for long-term outcomes, such as 90-day survival, and data related to specific organ blood flow remains mixed.

Evidence for Use in Ocular Dilation (Ophthalmic Solution)

The use of Phenylephrine in the eye has been evaluated in prospective comparative studies. The research examined its potential to cause pupil dilation (mydriasis), which is relevant in trials assessing short-term or episodic symptom patterns necessary for examination or preparation for surgery. Studies explored the time required for the pupil to reach its maximum size and the duration of the dilation effect.

Studies report how pupils evolved in the observed populations, generally finding that the solution was studied for measurements related to pupil dilation needed for internal eye examination. A major research limitation is that many studies rely on combination therapy, meaning the data are still emerging regarding the contribution of the Phenylephrine component alone in all scenarios. Comparative evidence is lacking for specific inflammatory eye conditions like anterior uveitis.

What Is Still Uncertain About Мезатон Research

Despite the existing body of research, several key limitations and evidence gaps remain. The overall evidence quality varies across studies, particularly for long-term outcomes beyond the acute phase of treatment. There is still limited information for long-term outcomes, such as the sustained effect on organ perfusion in critically ill patients, especially when compared with other standard vasopressors over an extended duration. Furthermore, the evidence base for the ophthalmic solution is still being developed concerning specific inflammatory outcomes.

Key Studies & References

1. Prophylactic Phenylephrine Increases the Dose Requirement of Oxytocin to Treat Uterine Atony During Cesarean Delivery (RCT examining impact on maternal outcomes/complications)

Common questions about Мезатон (FAQ)

---

Q: Is Мезатон an over-the-counter medicine or does it require a prescription?

A: The injectable form of Мезатон is administered only by healthcare professionals in a supervised clinical setting, which means this formulation is typically distributed as prescription-only. However, low-concentration topical forms of the active ingredient, phenylephrine, are commonly available over-the-counter for different uses.

---

Q: How quickly should I expect to feel the effects of Мезатон?

A: Official product information indicates that the onset of the blood pressure-raising effect following an intravenous injection is rapid. This characteristic quick action is essential for its use in acute care settings where immediate blood pressure support is needed.

---

Q: How long does the effect of Мезатон usually last?

A: Following a single intravenous injection, the blood pressure-raising effect may last for up to 20 minutes. If administered as a continuous intravenous infusion, the effective half-life of the drug in the body is noted to be approximately five minutes.

---

Q: Is it true that Мезатон can be used for eye redness?

A: The active ingredient in Мезатон, phenylephrine, has potent vasoconstrictive properties, causing blood vessels to narrow. While its primary ophthalmic use is to dilate the pupil, this constricting action, which narrows blood vessels, is consistent with treatments used to reduce swelling and redness.

---

Q: Can Мезатон cause sleep disturbances or insomnia?

A: Yes, regulatory documents list central nervous system effects such as sleeplessness (insomnia), nervousness, and excitability as reported side effects. These effects are related to the drug's sympathomimetic action on the nervous system.

---

Q: What are the serious but rare side effects of Мезатон?

A: Serious side effects documented in official labeling are generally related to the drug's powerful actions on the cardiovascular system. These include severe drops in heart rate (bradycardia), restriction of blood flow to the heart (myocardial ischemia), and potential tissue damage at the injection site (necrosis).

---

Q: Does caffeine increase the risk of side effects from Мезатон?

A: Regulatory documents caution against combining phenylephrine with other sympathomimetic agents, as these combinations can increase the risk of cardiovascular side effects. Users of any product containing phenylephrine should be aware of this general caution.

---

Q: Can older people use Мезатон without special precautions?

A: Regulatory information indicates that special caution is required for older (geriatric) patients. Dose selection should start at the lower end of the dosing range due to the greater likelihood of reduced heart, kidney, or liver function in this population.

---

Q: Is Мезатон safe to use during pregnancy (in general terms)?

A: The injectable form is typically used only when the potential benefit to the patient is judged to outweigh the potential risks to the fetus. This decision is based on a healthcare professional's assessment of the patient's critical need for the medication.

---

Q: Does the research evidence strongly support the use of Мезатон for shock?

A: Yes, regulatory approvals indicate the injectable form is used to treat clinically important low blood pressure (hypotension) that is primarily caused by blood vessel dilation. This includes hypotension that occurs in the settings of general anesthesia and certain types of septic shock.

---

Q: Can Мезатон affect blood sugar levels?

A: Phenylephrine belongs to a class of drugs called sympathomimetic agents, which may cause an increase in blood sugar (glucose) concentrations. Due to this potential effect, official labeling advises caution when administering the drug to patients with diabetes mellitus.

---

Q: Does taking Мезатон affect my ability to drive or operate machinery?

A: Because reported side effects include dizziness, tremor, and nervousness, official information suggests caution should be exercised regarding activities that require mental alertness, such as driving or operating machinery.

---

Q: Is it normal to feel a slight tingling sensation after using Мезатон?

A: Yes, paresthesia, which describes a tingling or numbing sensation, has been reported as a nervous system side effect of the injectable solution, according to official adverse reaction lists.

---

Q: How should Мезатон be stored?

A: The sterile solution for injection is required to be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The undiluted concentrate must be protected from light. Diluted solutions have specific and strict time limits for use after preparation.

---

Q: What are the specific signs of an overdose of Мезатон?

A: Overdosage is expected to severely increase the drug's effects. Signs may include dangerously high blood pressure (severe hypertension), intense headache, and potential cardiac irregularities.

---

Q: Is it normal to have elevated anxiety after taking Мезатон?

A: While the term 'anxiety' is not explicitly listed, official labels report side effects such as nervousness and excitability. These effects are closely related to anxiety and may be experienced by some individuals.

---

Q: What happens if I forget a dose of Мезатон?

A: The injectable form is used in critical care settings and is administered by healthcare professionals. Therefore, instructions regarding a 'missed dose' for self-administration are not applicable to the official product labeling.

---

Q: What kind of studies have been done on the long-term safety of Мезатон?

A: Clinical studies have primarily focused on the drug's effectiveness and safety during the acute phase of treatment (e.g., during surgery or ICU stay). Official evidence regarding the drug's safety over an extended, long-term period is generally limited.

---

Q: Why do some people feel dizzy when using Мезатон?

A: Dizziness is a reported side effect of the drug, according to regulatory documents. The dizziness may be related to the drug's effect on blood pressure or the central nervous system.

---

Q: Is there a generic version of Мезатон available?

A: Мезатон is a trade name for the active ingredient, Phenylephrine Hydrochloride. Generic versions containing the same active chemical compound are available on the market.

---

Q: Can Мезатон be used by people with a history of thyroid issues?

A: Official labeling advises caution for use in patients with underlying thyroid issues. Specifically, the high-concentration ophthalmic solution is contraindicated (should not be used) in patients with a severe overactive thyroid (Thyrotoxicosis).

---

Q: Is it okay to drink alcohol in moderation while on Мезатон?

A: Official information suggests that using phenylephrine with alcohol may increase side effects such as drowsiness, dizziness, or nausea. This combination is generally not recommended.

---

Q: Can Мезатон cause dry mouth?

A: Dry mouth and dryness in the nose or throat have been reported as common side effects of drug products containing phenylephrine.

---

Q: Can using Мезатон affect the results of any medical tests?

A: As a sympathomimetic amine, phenylephrine can potentially interfere with certain laboratory analyses. For instance, official information notes that it can cause false positive results in some drug screening tests for amphetamines.

---

Q: Why is Мезатон not recommended for infants?

A: The safety and effectiveness of the injectable solution have not been established for use in children. Furthermore, certain high-concentration eye drop forms are contraindicated in children less than one year old due to risks associated with systemic absorption.

---

Q: How is the efficacy of Мезатон measured in clinical settings?

A: The effectiveness of the injectable form is primarily measured by the resulting increase in mean arterial pressure (MAP). For the ophthalmic solution, efficacy is measured by the degree and duration of pupil dilation achieved.

Storage and Handling Requirements

The sterile solution for injection (Phenylephrine Hydrochloride) must be stored under specific conditions to maintain stability, as required by regulatory labeling.

Required Conditions

Condition	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F).
Light Protection	Undiluted solution must be protected from light.
Post-Dilution Limit	Use the diluted solution within 4 hours at room temperature or 24 hours if refrigerated (2 C to 8 C).

Child-Safety and Disposal

All preparations must be stored out of the sight and reach of children. Solutions must be visually inspected before use, and the product should not be used if it appears colored or contains particulate matter. Any unused portion of the diluted injection solution must be discarded, and disposal of expired product should follow local regulations.